SecBot SecBot
8-K ·Filed Jul 23, 2026

UTMD

UTAH MEDICAL PRODUCTS INC
BEARISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001096906-26-001112
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The guidance cut is the most significant signal, the lost customer revenue is not being replaced quickly enough. Traders should watch the upcoming 10-Q filing for segment-level detail and any updates on new biopharma customer wins. Given the prolonged revenue decline, UTMD may need to pivot to cost-cutting or M&A to stabilize earnings. The stock's 23% YTD gain (to $68.98) may face headwinds if the market reprices for lower growth.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$64.18
T+0 close · Jul 23, 2026 · via day close
Latest settled
+16.73%
T+60 · $74.92
Vs SPY
+12.18%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 23 $64.18entry
  2. T+1 · 4mo ago +4.61%α +4.51% · $67.14
  3. T+5 · 4mo ago +8.40%α +7.92% · $69.57
  4. T+20 · 3mo ago +11.28%α +7.97% · $71.42
  5. T+60 · 5w ago +16.73%α +12.18% · $74.92
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

UTMD reported Q2 2026 revenue of $8.5M, down 14.3% YoY, and EPS of $0.844, down 10.1% YoY, reflecting the continued loss of its two largest customers (PendoTECH and China distributor). Management lowered full-year 2026 revenue guidance to a 10-13% decline from prior expectations of flat sales, as new product sales to biopharma customers have been slower than anticipated. The balance sheet remains debt-free with $87.5M cash, but the top-line trajectory and guidance cut signal ongoing headwinds.

Key Financial Metrics

EPS
$0.84
Revenue
$8.5M
-14.3% YoY
Rating
strong miss
Gross Margin
55.8%

Key Facts

  • Q2 2026 revenue fell 14.3% to $8.53M vs $9.95M in Q2 2025; EPS declined 10.1% to $0.844 from $0.939
  • Full-year 2026 revenue guidance lowered to a 10-13% decline (from prior expectation of flat vs 2025) due to slower-than-expected new product sales
  • Loss of two former largest customers (PendoTECH OEM and China distributor) accounted for 75% of the Q2 revenue decline
  • Litigation expense guidance raised: 2026 now expected to be less than $1.6M (vs $1.355M in 2025), reversing prior expectation of a decline
  • Balance sheet remains strong with $87.5M cash and no debt; share repurchases minimal at $0.2M in 1H 2026 vs $6.7M in 1H 2025

Financial Impact

Revenue decline of $1.42M in Q2 and $2.41M in 1H; EPS decline of 10.1% in Q2. Full-year guidance implies $3-4M revenue shortfall vs prior plan.

revenueepsoperating incomelitigation expenses

Risk Factors

  • Continued revenue concentration risk, two former customers accounted for $2.9M in 2025 sales with no replacement yet
  • Litigation expenses could exceed the revised $1.6M estimate if cases go to trial
  • Operating leverage works in reverse, fixed manufacturing overhead and G&A (health plan, litigation) compress margins on lower sales
  • New product sales to biopharma OEM customers are developing slower than expected, delaying the revenue recovery

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001096906-26-001112
Document: utmd-20260723_8k.htm0001096906-26-001112
Document: 0001096906-26-001112-index-headers.html0001096906-26-001112
Document: 0001096906-26-001112-index.html0001096906-26-001112
Document: 0001096906-26-001112.txt0001096906-26-001112
8-K Data (Synthetic)0001096906-26-001112

US Market Status

Market Closed · Opens in 5h 57m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 23, 2026